Article Text

PDF
A prospective study of the immediate and delayed adverse events following intravenous immunoglobulin infusions
  1. D Singh-Grewal1,
  2. A Kemp2,
  3. M Wong1
  1. 1Department of Allergy, Immunology and Infectious Diseases, The Children’s Hospital at Westmead, Sydney, Australia
  2. 2Discipline of Paediatrics and Child Health, The Children’s Hospital at Westmead Clinical School, University of Sydney, Sydney, Australia
  1. Correspondence to:
    Prof. A Kemp
    Department of Allergy Immunology and Infectious Diseases, The Children’s Hospital at Westmead, Locked Bag 4001, Westmead, Sydney, New South Wales, Australia 2145; andrewk5{at}chw.edu.au

Abstract

Aim: To document the incidence of immediate and delayed adverse events (AE) following intravenous immunoglobulin (IVIG) infusion in children.

Methods: Immediate and delayed adverse events were prospectively recorded for 345 infusions in 58 children receiving IVIG for immunodeficiency (n = 33) or immunomodulation (n = 25). For each infusion adverse events were documented during the infusion and by follow up interview 4–7 days later.

Results: Immediate adverse events occurred in 10.3% and delayed adverse events in 41.4% of children treated during the study period. Three and a half per cent of the infusions were associated with immediate AE and 20.9% with delayed adverse events. Headache was the most common delayed AE, occurring in 24.1% of patients and 12.8% of infusions.

Conclusions: Delayed adverse events to IVIG infusions are common in children. They occur more frequently than immediate adverse events and are the cause of significant morbidity. Recognition of the high frequency of delayed adverse events is important in the care of children receiving IVIG therapy.

  • AE, adverse event
  • IVIG, intravenous immunoglobulin
  • immunoglobulins
  • intravenous
  • adverse effects
  • headache
  • immunologic deficiency syndromes

Statistics from Altmetric.com

Footnotes

  • Published Online First 25 April 2006

  • Competing interests: Professor Kemp was the author of a clinical expert report for CSL in 1997 and his superannuation fund owns some shares in CSL.

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.